MedTrace Logo

Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis

NCT07571525 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-05-06

No results posted yet for this study

Summary

The goal of this observational study is to investigate the clinical, immunological, and neuromuscular features associated with the development and progression of myasthenia gravis (MG) in adult patients with thymic abnormalities and/or MG-related antibodies, including individuals with or without clinically manifest disease.

The main questions it aims to answer are:

* Whether integrated clinical, serological, and histopathological profiles are associated with the presence of MG and can predict disease onset or progression
* Wheter systemic immune markers are associated with disease activity, progression, and neuromuscular junction alterations

Participants will:

* Undergo clinical, neurological, and neurophysiological assessments at baseline and during follow-up
* Provide blood samples for serological and immunological analyses
* Provide thymic tissue and residual intercostal muscle samples (when undergoing clinically indicated thymectomy) for research analyses
* Attend follow-up visits at 6, 12, and 18 months
* Record daily symptoms using an electronic patient-reported outcome tool (for participants with MG)

Conditions

  • Myasthenia Gravis (MG)
  • Myasthenia Gravis Associated With Thymoma
  • Thymoma

Sponsors & Collaborators

  • IRCCS San Raffaele

    lead OTHER

Principal Investigators

  • Stefano C Previtali · IRCCS Ospedale San Raffaele

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-15
Primary Completion
2029-09-14
Completion
2029-12-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07571525 on ClinicalTrials.gov